PubMed HealthSearch

PubMed · 318115

[Levamisole as an immunostimulating factor].

Abstract

Levamisole--(L)--1-2, 3, 5, 6--tetrahydro-6- phenylimidazo (2, 1-b)-- thiazol monohydrochloride, a simple chemical, first introduced as a broad spectrum antihelmintic , has been recently on the list of the nonspecific active immunostimulants together with BCG, Corynebacterium parvum, polyribonucleosides and transfer factor (TF). This, however, is oversimplification and may cause some confusion because levamisole, in contrast to the so-called immunostimulants, does not stimulate immunity above the normal level in man or prevent the primary growth of most experimental tumors in immunologically normal animals. Levamisole acts as an antianergic chemotherapeutic agent as it restores cell-mediated immunity in immunodepressed patients and prolongs the remission period. It even increases the number of long-term survivors when used as an adjunct to cytoreductive therapy in several animal cancer models. Levamisole is rapidly absorbed from the gastrointestinal tract and from injection site and is very well distributed in all tissues. Levamisole increases phagocytosis by polymorphonuclear cells or macrophages when added to these cells or given to donor animals and humans. The effect was pronounced on hypofunctional cells from patients and it was weak or absent on cells from normal donors. Chemotactic responsiveness of polymorphonuclear cells and monocytes from patients with defective leucocyte motility could be enhanced by levamisole added in vitro or given in vivo. The leucocyte migration inhibition in response to antigenic stimulation could be restored when levamisole was administered to anergic patients or added to their cells in vitro.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Smogorzewska. 1979. [Levamisole as an immunostimulating factor].. https://pubmed.ncbi.nlm.nih.gov/318115/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Active, specific immunotherapy of murine leukemia. II. Adjuvant effect of Corynebacterium parvum.

We have previously shown that irradiated LSTRA cells (LX) were immunogenic and could prolong survival of mice bearing LSTRA tumors. This study demonstrated that addition of Corynebacterium parvum to the LX dramatically improved the strength of tumor immunity. In pretreatment-challenge experiments, C. parvum augmented the immunogenicity of 10(6) LX given intradermally, with an optimum dose of 0.14-1.4 microgram C. parvum per mouse. In therapy experiments (intraperitoneal vaccine treatment after tumor cell challenge), the therapeutic effect of 10(7) LX was improved by admixture of C. parvum, leading to a larger number of cured mice, permitting treatment of a larger challenge inoculum, and allowing later initiation of treatment than was possible with LX alone. Optimal dose of C. parvum for therapy was 1,400 microgram per mouse. Presensitization to C. parvum or use of repeated vaccine injections did not further improve the therapeutic effect. Cure of tumor-bearing mice by the mixed vaccine was tumor-specific. These results suggest that C. parvum is a potent adjuvant for use in active, tumor-specific immunotherapy.

Adjuvants, Immunologic

Augmentation of natural killer activity by pyran copolymer in mice.

Treatment of older mice with pyran copolymer, a known interferon-inducer, was found to result in a rapid boosting of cell-mediated cytolytic activity against YAC-1 tumor target cells. The effector cells were characterized as being non-adherent and were presumed to be natural killer (NK) cells. Augmentation occurred in various lymphoid organs and was detectable 2-3 days after drug treatment. Differences in the levels of boosted activity among the lymphoid organs resulted when the route of administration was varied. The degree of augmentation was largely independent of the dose of pyran, but did vary among different strains of mice. Augmentation, moreover, was followed by a rapid decline by 5-7 days.

Adjuvants, Immunologic